Cited by 231Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin

Open access

Hsia, Judith, MacFadyen, Jean G., Monyak, John, Ridker, Paul M.·2011·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2010.09.082

Open this paper in CoChat — free account Open PDF

Abstract

Objectives The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial.Background The safety and magnitude of cardiovascular risk reduction conferred by treatment to LDL-C levels below current recommended targets remain uncertain.Methods A cohort of 17,802 apparently healthy men and women with high-sensitivity C-reactive protein ≥2 mg/l and LDL-C <130 mg/dl were randomly allocated to rosuvastatin 20 mg daily or placebo, and followed up for all-cause mortality, major cardiovascular events, and adverse events. In a post-hoc analysis, participants allocated to rosuvastatin were categorized as to whether or not they had a follow-up LDL-C level <50 mg/dl.Results During a median follow-up of 2 years (range up to 5 years), rates of the primary trial endpoint were 1.18, 0.86, and 0.44 per 100 person-years in the placebo group (n = 8,150) and rosuvastatin groups without LDL-C <50 mg/dl (n = 4,000) or with LDL-C <50 mg/dl (n = 4,154), respectively (fully-adjusted hazard ratio: 0.76; 95% confidence interval: 0.57 to 1.00 for subjects with no LDL-C <50 mg/dl vs. placebo and 0.35, 95% confidence interval: 0.25 to 0.49 for subjects attaining LDL-C <50 mg/dl; p for trend <0.0001). For all-cause mortality, corresponding event rates were 0.67, 0.65, and 0.39 (p for trend = 0.004). Rates of myalgia, muscle weakness, neuropsychiatric conditions, cancer, and diabetes mellitus were not significantly different among rosuvastatin-allocated participants with and without LDL-C <50 mg/dl.Conclusions Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein ≥2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2010.09.082

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453

Show all 41 references

Sorted by citations

Items 101–200 of 231

Statin Adverse Events in Primary Prevention: Between Randomized Trials and Observational Studies
Mansi, I. A., & Palmer, B. F. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000527 · Cited by 15
Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study
Itoh, H., Komuro, I., Takeuchi, M., Akasaka, T., Daida, H., Egashira, Y., Fujita, H., Higaki, J., Hirata, K., Ishibashi, S., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13575 · Cited by 15
Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista
Ascaso, J. F., & Carmena, R. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.07.002 · Cited by 14
Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention
Jiao, Y., Hu, F., Zhang, Z., Gong, K., Sun, X., Li, A., & Liu, N. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0335-1 · Cited by 14
Safety of Combined Statin and Fibrate Therapy: Risks of Liver Injury and Acute Kidney Injury in a Cohort Study from the Shizuoka Kokuho Database
Sobukawa, Y., Hatta, T., Funaki, D., & Nakatani, E. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00426-1 · Cited by 13
Assessment of Low-Density Lipoprotein Targets
Whayne, T. F. (2012) · Angiology · doi:10.1177/0003319712451115 · Cited by 13
Problems and Possible Solutions for Therapy with Statins
Whayne, T. F. (2013) · International Journal of Angiology · doi:10.1055/s-0033-1343358 · Cited by 13
Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies
Sahebkar, A., & Watts, G. F. (2014) · Clinical Lipidology · doi:10.2217/clp.14.14 · Cited by 13
Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels
Qamar, A., & Bhatt, D. L. (2015) · Circulation Research · doi:10.1161/circresaha.115.307345 · Cited by 13
Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia
Goodall, L., Lennon, M. J., Sachdev, P. S., Gorelick, P. B., Kovacic, J. C., & Samaras, K. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1502 · Cited by 14
Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial
Cha, J., Hong, S. J., Kim, J. H., Lim, S., Joo, H. J., Park, J. H., Yu, C. W., Lee, P. H., Lee, S., Lee, C. W., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.03.002 · Cited by 12
Treating Dyslipidemia in Type 2 Diabetes
Nelson, A. J., & Nicholls, S. J. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.005 · Cited by 13
Statins and risk of cancer: A meta-analysis of randomized, double-blind, placebo-controlled trials
Kim, M. K., Myung, S., Tran, B. T., & Park, B. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_214_17 · Cited by 12
The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy
Caso, V. M., Sperlongano, S., Liccardo, B., Romeo, E., Padula, S., Arenga, F., D’Andrea, A., Caso, P., Golino, P., Nigro, G., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030475 · Cited by 11
Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States
Unni, S. K., Quek, R. G. W., BISKUPIAK, J. E., Lee, V. C., Ye, X., & Gandra, S. R. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.09.008 · Cited by 11
Statins for primary prevention of venous thromboembolism
Li, L., Sun, T., Zhang, P., Tian, J., & Yang, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008203.pub2 · Cited by 12
Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain
Cosı́n-Sales, J., Sidelnikov, E., Villamayor, S., Fernández, M., Merino-Montero, S., & Zamora, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02384-y · Cited by 10
No effect of high-dose atorvastatin on leukotriene B4 formation from neutrophils in patients treated with coronary bypass surgery:
Lysgaard, C., Nielsen, M. S., Christensen, J., Lundbye‐Christensen, S., Riahi, S., & Schmidt, E. B. (2012) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2012.09.004 · Cited by 10
What Can We Learn About Valvular Heart Disease From PET/CT?
Jenkins, W. S. A., Chin, C., Rudd, J. H. F., Newby, D. E., & Dweck, M. R. (2013) · Future Cardiology · doi:10.2217/fca.13.47 · Cited by 10
Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia
Whayne, T. F. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0150-3 · Cited by 11
PCSK9 inhibitors in the current management of atherosclerosis
Whayne, T. F. (2016) · Archivos de cardiología de México · doi:10.1016/j.acmx.2016.11.013 · Cited by 11
Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia
Cao, Y., Li, L., Zhang, H., Jin, J., Liu, H., Guo, Y., Wu, N., Zhu, C., Dong, Q., Xu, R., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5324 · Cited by 10
Safety and efficacy of moderate‐intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease
Cha, J., Kim, J. H., Hong, S. J., Lim, S., Joo, H. J., Park, J. H., Yu, C. W., Lee, P. H., Lee, S., Lee, C. W., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20029 · Cited by 10
PCSK9 Inhibitors and Their Role in high-risk Patients in Reducing Ldl Cholesterol Levels: Alirocumab
Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A. D., Feinstein, M. J., Qamar, A., Joshi, P. H., Swiger, K. J., Byrne, K., Quispe, R., et al. (2016) · Future Cardiology · doi:10.2217/fca.15.88 · Cited by 10
A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study
Štulc, T., Lánská, V., Šnejdrlová, M., Vrablı́k, M., Prusíková, M., & Češka, R. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.64865 · Cited by 9
Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial
Toth, P. P., Jones, S. R., Slee, A. E., Fleg, J. L., Marcovina, S. M., Lacy, M., McBride, R., & Boden, W. E. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.077 · Cited by 9
Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases
Kostapanos, M. S., Rizos, C. V., & Elisaf, M. (2014) · Drug Safety · doi:10.1007/s40264-014-0169-4 · Cited by 9
Adverse drug reaction: rosuvastatin as a cause for ischaemic colitis in a 64-year-old woman
Tan, J., Pretorius, C., Flanagan, P. V., & Pais, A. (2012) · BMJ Case Reports · doi:10.1136/bcr.11.2011.5270 · Cited by 9
Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction
Toth, P. P. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.05.028 · Cited by 9
Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters
Lee, C. H., Hwang, J., Kim, I., Cho, Y., Park, H., Yoon, H., Kim, H., Han, S., Hur, S., Kim, K.-B., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.07.010 · Cited by 9
Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
Piña, P., Lorenzatti, D., Paula, R., Daich, J., Schenone, A. L., Gongora, C. A., Garcia, M. J., Blaha, M. J., Budoff, M. J., Berman, D. S., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100451 · Cited by 10
Prevention of Carotid Artery Atherosclerosis: What is the Evidence?
Whayne, T. F. (2016) · Angiology · doi:10.1177/0003319716669460 · Cited by 9
Lower cardiovascular mortality with atorvastatin and rosuvastatin vs simvastatin: Data from “moderate-intensity” statin users in an observational registry on chronic heart failure (Daunia Heart Failure Registry)
Brunetti, N. D., Correale, M., Totaro, A., Ferraretti, A., Monaco, I., Passero, T., Gennaro, L. D., & Biase, M. D. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.041 · Cited by 8
Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Qamar, A., & Libby, P. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1160-6 · Cited by 8
Statins: pros and cons
Pinal‐Fernandez, I., Casal-Domínguez, M., & Mammen, A. L. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.03.001 · Cited by 8
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk
Nicholls, S. J., Uno, K., & Kataoka, Y. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.145 · Cited by 8
Association between statin treatment and LDL-cholesterol levels on the rate of ST-elevation myocardial infarction among patients with acute coronary syndromes: ACS Israeli Survey (ACSIS) 2002–2010
Gottlieb, S., Kolker, S., Nir, S., Matetzky, S., Leitersdorf, E., Segev, A., Goldenberg, I., Tzivoni, D., Weisz, G., & Moriel, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.088 · Cited by 8
Imaging to Stratify Coronary Artery Disease Risk in Asymptomatic Patients with Diabetes
Malahfji, M., & Mahmarian, J. J. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-4-266 · Cited by 8
PCSK9 Inhibitors: From Nature’s Lessons to Clinical Utility
Raal, F. J., CHILTON, R. J., Ranjith, N., Rambiritch, V., Leisegang, R. F., Ebrahim, I. O., van Tonder, A., Shunmoogam, N., Bouharati, C., Musa, M. G., et al. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200213114138 · Cited by 8
Lipidomics and cognitive dysfunction – A Narrative review
Chakraborty, A., Praharaj, S. K., Prabhu, R. V. K., & Prabhu, M. M. (2020) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2020-0134 · Cited by 8
Statin use and breast cancer: do we need more evidence and what should this be?
Bonovas, S., Lytras, T., & Sitaras, N. M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.888806 · Cited by 8
LDL-Cholesterol Targets After the ACC/AHA 2013 Guidelines
Ben‐Yehuda, O., & DeMaria, A. N. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.020 · Cited by 8
Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates
Gusarova, V., HOWARD, V. G., Okamoto, H., Koehler-Stec, E. M., Papadopoulos, N. J., Murphy, A. J., Yancopoulos, G. D., Stahl, N., & Sleeman, M. W. (2012) · Clinical Lipidology · doi:10.2217/clp.12.70 · Cited by 7
CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia
Siddiqui, M. K., Veluchamy, A., Maroteau, C., Tavendale, R., Carr, F., Pearson, E. R., Colhoun, H. M., Morris, A. D., Casella, G., Doney, A. S. F., et al. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001737 · Cited by 7
Self-citation
Low LDL-C Levels
Robinson, J. G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.040 · Cited by 7
Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP)
Banach, M., Toth, P. P., Ahn, H., Bielecka-Dabrowa, A. M., Cicero, A. F. G., Covic, A. C., Dalakoti, M., Escobar, C., Fogacci, F., Gaiță, D. I., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.11.003 · Cited by 8
Statins for the primary prevention of venous thromboembolism
Wang, Z., Zhang, P., Tian, J., Zhang, P., Yang, K., & Li, L. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014769.pub2 · Cited by 6
RETRACTED ARTICLE: Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report
Kim, K. M., Jung, K. Y., Yun, H. M., Lee, S. Y., Oh, T. J., Jang, H. C., & Lim, S. K. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0629-0 · Cited by 6
Retracted
The association of repeatedly measured low-density lipoprotein cholesterol and all-cause mortality and cardiovascular disease in dyslipidemic patients: A longitudinal study
Kobayashi, D., Mizuno, A., Shimbo, T., Aida, A., & Noto, H. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.011 · Cited by 6
The Role of Statin Therapy for Primary Prevention: What is the Evidence?
Ascunce, R. R., Berger, J. S., WEINTRAUB, H. S., & Schwartzbard, A. Z. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0229-0 · Cited by 6
Critical review of non-statin treatments for dyslipoproteinemia
Pang, J., Chan, D. C., & Watts, G. F. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.888312 · Cited by 6
The Evolution or Revolution of Statin Therapy in Primary Prevention: Where Do We Go From Here?
Rehfield, P., Kopes-Kerr, C. P., & Clearfield, M. B. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0298-0 · Cited by 6
Niveles óptimos de colesterol en los pacientes con dislipemia. Revisión sistemática de la evidencia
Escobar, C., Barrios, V., & de Isla, L. P. (2017) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2017.08.006 · Cited by 5
Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists
Jahangir, A., Sahra, S., & Krzyzak, M. (2021) · Cureus · doi:10.7759/cureus.16664 · Cited by 7
PCSK9 Inhibitors and Their Role in high-risk Patients in Reducing Ldl Cholesterol Levels: Evolocumab
Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A. D., Feinstein, M. J., Qamar, A., Joshi, P. H., Swiger, K. J., Byrne, K., Quispe, R., et al. (2016) · Future Cardiology · doi:10.2217/fca.15.89 · Cited by 5
Statins: An Update on Clinical Issues and Selected Adverse Effects
Gulum, A. H., & Hume, A. L. (2015) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2014.09.004 · Cited by 5
Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients
Soubra, L., Domiati, S. A., & Fattouh, Y. (2017) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-017-0483-x · Cited by 5
Lipid-modifying and antiatherosclerotic drugs
Gotto, A. M., & Opie, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00019-3 · Cited by 5
Can We Eliminate Low-Density Lipoprotein Cholesterol-Related Cardiovascular Events Through More Aggressive Primary Prevention Therapy?
Mancini, G. B. J., & Hegele, R. A. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.027 · Cited by 5
Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond
Agha, A. M., Virani, S. S., & Ballantyne, C. M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000608 · Cited by 4
Searching the place of pitavastatin in the current treatment of patients with dyslipidemia
Barrios, V., Escobar, C., & Zamorano, J. L. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.844546 · Cited by 4
Guideline Confusion for the Clinician
Whayne, T. F. (2014) · Angiology · doi:10.1177/0003319714559122 · Cited by 4
Controllo lipidico in pazienti ad elevato rischio cardiovascolare: focus sull’inibizione di PCSK9
Filardi, P. P., Paolillo, S., & Trimarco, B. (2015) · Giornale italiano di cardiologia · doi:10.1714/1776.19250 · Cited by 4
Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management
Whayne, T. F. (2016) · International Journal of Angiology · doi:10.1055/s-0036-1597129 · Cited by 4
Cardiovascular Risk Factor Modification in Asymptomatic Adults and Implications for Pilots
Wirawan, I. M. A., Griffiths, R. F., & Larsen, P. (2020) · Journal of UOEH · doi:10.7888/juoeh.42.187 · Cited by 4
Influence and Critique of the JUPITER Trial (Statins v No Statins for Primary Prevention of Cardiovascular Events in Patients with Normal Lipids and Elevated C-Reactive Protein)
Samson, R. H., & Nair, D. G. (2011) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2011.10.005 · Cited by 4
A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals
Bays, H. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.006 · Cited by 4
Rhabdomyolysis is a rare complication of statin therapy. Case report and literature review
Sumarokov, A. M., Чубыкина, У. В., & Владиславович, Е. М. (2022) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20221701184 · Cited by 3
The prognostic role of the low and very low baseline LDL-C level in outcomes of patients with cardiac revascularization; comparative registry-based cohort design
Rezaee, M., Fallahzadeh, A., Sheikhy, A., Ajam, A., Sadeghian, S., Bsc, M. P., Shirzad, M., Mansourian, S., Bagheri, J., & Hosseini, K. (2023) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-023-02333-y · Cited by 4
Rosuvastatin repurposing for prophylaxis against ethanol-induced acute gastric ulceration in rats: a biochemical, histological, and ultrastructural perspective
Elkerdasy, H., Faruk, E. M., Hassan, D. A. A., Nafea, O. E., Ibrahim, F., Bagabir, R. A., Anwer, H. M., & Allam, A. M. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01513-z · Cited by 3
Pharmacological Profile and Mechanisms of Cardiovascular Protective Effects of Statins: An Update
Elhwuegi, A. S., & Elfakhri, M. (2025) · Libyan International Medical University Journal · doi:10.1055/s-0045-1809043 · Cited by 5
Optimal lipid targets for the new era of cardiovascular prevention
Ramjee, V., Eapen, D. J., & Sperling, L. S. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06478.x · Cited by 3
Evolving Concepts in LDL-Lowering Strategies: Are We There?
Cimmino, G., Loffredo, F. S., Arena, G., & Golino, P. (2016) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000468 · Cited by 3
Lipid control in patients with coronary artery disease in a healthcare area in Cáceres (Spain): LIPICERES study
Gómez-Barrado, J. J., Ortiz, C., Gómez-Turégano, M., Gómez-Turégano, P., de Vargas, F. J. G., & Sánchez-Calderón, P. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2016.09.001 · Cited by 3
Lipid-lowering therapy treatment regimens in high- and very high-risk patients for the prevention of cardiovascular events: results from the Irish cohort of the multinational, observational SANTORINI study
Rai, H., Coughlan, J. J., O’Callaghan, D., Sheahan, R. G., Murphy, R. T., Burke, D., McFadden, E. P., Nolan, D., Colleran, R., Hazeez-Agbaje, A., et al. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-04096-y · Cited by 2
Attaining LDL-cholesterol target post major coronary event: Care gap, associated factors and clinical outcomes
Iribarren, C., Lu, M., Go, A. S., Rana, J. S., Ngai, K., & Rogers, A. M. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107430 · Cited by 2
Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents
Kohli, P., & Giugliano, R. P. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413480270 · Cited by 2
Highlights of the Year in JACC 2011
DeMaria, A. N., Bax, J. J., Ben‐Yehuda, O., Feld, G. K., Greenberg, B., Hall, J., Hlatky, M. A., Lew, W. Y. W., Lima, J. A. C., Maisel, A. S., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.013 · Cited by 2
Statins in Peripheral Arterial Disease
Chiesa, S. T., Παπαγεωργίου, Ν., & Charakida, M. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170926130826 · Cited by 2
Lipemia poposiłkowa — problem kliniczny i potencjalne miejsce w algorytmach diagnostycznych Stanowisko polskich ekspertów
Skoczyńska, A., Wawrzynowicz‐Syczewska, M., Barlik-Rysa, M., Danik, A., Różański, J., Filipiak, K. J., & Cybulska, B. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0001 · Cited by 1
An Anti-Inflammatory Approach in the Therapeutic Choices for the Prevention of Atherosclerotic Events
Pende, A., & Denegri, A. (2012) · InTech eBooks · doi:10.5772/31565 · Cited by 1
Nuevos tratamientos para la hipercolesterolemia
Pintó, X., & Gómez, M. C. G. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.01.016 · Cited by 2
Hypercholesterinämie – Wo stehen wir heute? Wo wollen wir hin?
Gitt, A. K., & Zahn, R. (2016) · Herz · doi:10.1007/s00059-016-4457-x · Cited by 2
Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease
Almarzooq, Z., & Singh, P. (2016) · InTech eBooks · doi:10.5772/64762 · Cited by 2
New agents for hypercholesterolemia
Pintó, X., & Gómez, M. C. G. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.04.058 · Cited by 2
The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention
Pandey, A. S., BAJAJ, H. S., Garg, V., Pandey, A., & Verma, S. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000424 · Cited by 3
Time-varying effect of postoperative cholesterol profile on long-term outcomes of isolated coronary artery bypass graft surgery
Ayati, A., Akbari, K., Shafiee, A., Zoroufian, A., Jalali, A., Samimi, S., Pashang, M., Hosseini, K., Bagheri, J., & Masoudkabir, F. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01927-8 · Cited by 2
Management of Hypertension and Associated Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease
Rahbari-Oskoui, F. F. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.03.004 · Cited by 2
Statins
McKenney, J. M., & Roth, E. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00021-9 · Cited by 2
Prevalence and characteristics of patients with low levels of low-density lipoprotein cholesterol in northern Denmark: a descriptive study
Schmidt, S. A. J., Heide‐Jørgensen, U., Manthripragada, A. D., & Ehrenstein, V. (2015) · Clinical Epidemiology · doi:10.2147/clep.s77676 · Cited by 1
El largo trecho para llegar a los objetivos en el tratamiento de las dislipemias
Pintó, X. (2012) · Revista Clínica Española · doi:10.1016/j.rce.2012.07.005 · Cited by 1
Cardiovascular Autonomic Neuropathy: Risk Factor or Risk Indicator
Colombo, J., Arora, R. R., DePace, N. L., & Vinik, A. I. (2014) · Springer eBooks · doi:10.1007/978-3-319-07371-2_9 · Cited by 1
Statins and Mipomersen: Mechanisms of Action and Patient Tolerability
Pang, J., Chan, D. C., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_7 · Cited by 1
Less is More: Benefit of Achieving Very Low Low-Density Lipoprotein-Cholesterol Levels on Cardiovascular Events
Fatima, A., Chhaparia, A., & Qamar, A. (2017) · Heart Research - Open Journal · doi:10.17140/hroj-4-134 · Cited by 1
HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW
Bubnova, M. G. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-6-191-201 · Cited by 1
Estudio IMPROVE-IT. Buenas noticias para ezetimiba y para los pacientes
Escobar, C., Divisón, J. A., & Díaz, M. S. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2014.12.003 · Cited by 1
Knowledge of PCSK9 and Continued Educational Gaps
Larkin, A. T., HEALY, C. S., & Toth, P. P. (2015) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000036 · Cited by 1
Accidente isquémico transitorio tras espaciar la dosis de alirocumab: ¿es recomendable reducir las dosis de iPCSK9 ante c-LDL muy bajos?
Ruiz, S. P., Parra‐Virto, A., do Rego, A. T., Rodríguez, P. D., & Álvarez-Sala, J. L. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.003 · Cited by 1
Hypercholesterolemia, Lipid-Lowering Strategies and Microcirculation
Padró, T., Vilahur, G., & Badimón, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-28199-1_16 · Cited by 1
Treatment of Blood Cholesterol to Reduce Atheroscelerotic Cardiovascular Risk in Adults
Gray, C., & Stern, C. S. (2019) · Journal of Contemporary Pharmacy Practice · doi:10.37901/jcphp18-00004 · Cited by 1

Authors: Hsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M.
Affiliations: AstraZeneca (United States) (US)
Brigham and Women's Hospital (US)
Corresponding author: Hsia, Judith
ORCID: Hsia, Judith
Monyak, John
Ridker, Paul M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2011-04
Volume: 57
Issue: 16
Pages: 1666-1675
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2010.09.082
OpenAlex: W166112863
Cited by: 231
References: 41
Citations by year: 2026: 3 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 12 · 2021: 8 · 2020: 10 · 2019: 15 · 2018: 14 · 2017: 23 · 2016: 23 · 2015: 30 · 2014: 20 · 2013: 22 · 2012: 19
FWCI: 23.22
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 837 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca LP
AstraZeneca
Novartis
Merck
Abbott
Roche
Sanofi-Aventis
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: rosuvastatin, LDL cholesterol, cardiovascular risk reduction, high-sensitivity C-reactive protein, JUPITER trial, statin safety, all-cause mortality, major adverse cardiovascular events, myalgia, diabetes mellitus, cancer, neuropsychiatric adverse effects, hypercholesterolemia, inflammation, cardiovascular disease prevention
MeSH terms: Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Humans, Cholesterol, LDL, Male, Middle Aged, Pyrimidines, Sulfonamides, Cohort Studies, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks